These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 16206346

  • 21. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
    Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J.
    Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444
    [Abstract] [Full Text] [Related]

  • 22. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
    Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J.
    Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
    [Abstract] [Full Text] [Related]

  • 23. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD, Sack KE, Davis JC.
    N Engl J Med; 2002 May 02; 346(18):1349-56. PubMed ID: 11986408
    [Abstract] [Full Text] [Related]

  • 24. Etanercept in adult patients with early onset ankylosing spondylitis.
    Inman RD, Clegg DO, Davis JC, Whitmore JB, Solinger A.
    J Rheumatol; 2006 Aug 02; 33(8):1634-6. PubMed ID: 16881118
    [Abstract] [Full Text] [Related]

  • 25. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis.
    Henrickson M, Reiff A.
    J Rheumatol; 2004 Oct 02; 31(10):2055-61. PubMed ID: 15468375
    [Abstract] [Full Text] [Related]

  • 26. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
    Baraliakos X, Brandt J, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J.
    Arthritis Rheum; 2005 Dec 15; 53(6):856-63. PubMed ID: 16342093
    [Abstract] [Full Text] [Related]

  • 27. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis.
    Maksymowych WP, Rahman P, Shojania K, Olszynski WP, Thomson GT, Ballal S, Wong RL, Inman RD, M03-606 Study Group.
    J Rheumatol; 2008 Oct 15; 35(10):2030-7. PubMed ID: 18785308
    [Abstract] [Full Text] [Related]

  • 28. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
    Heiberg MS, Nordvåg BY, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2005 Aug 15; 52(8):2506-12. PubMed ID: 16052584
    [Abstract] [Full Text] [Related]

  • 29. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.
    Davis JC, Van der Heijde DM, Dougados M, Braun J, Cush JJ, Clegg DO, Inman RD, de Vries T, Tsuji WH.
    J Rheumatol; 2005 Sep 15; 32(9):1751-4. PubMed ID: 16142873
    [Abstract] [Full Text] [Related]

  • 30. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.
    Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, van der Heijde D, Braun J.
    Ann Rheum Dis; 2008 Apr 15; 67(4):511-7. PubMed ID: 17644552
    [Abstract] [Full Text] [Related]

  • 31. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis.
    Gadsby K, Deighton C.
    Rheumatology (Oxford); 2007 Mar 15; 46(3):439-41. PubMed ID: 17255137
    [Abstract] [Full Text] [Related]

  • 32. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.
    Davis JC, van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D, Inman RD, Kivitz A, Zhou L, Solinger A, Tsuji W.
    Ann Rheum Dis; 2005 Nov 15; 64(11):1557-62. PubMed ID: 15843448
    [Abstract] [Full Text] [Related]

  • 33. The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-α inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China.
    Xu M, Lin Z, Deng X, Li L, Wei Y, Liao Z, Li Q, Wei Q, Hu Z, Zhang Y, Lin Q, Huang J, Li T, Pan Y, Wu Y, Jin O, Yu B, Gu J.
    Rheumatology (Oxford); 2011 Aug 15; 50(8):1466-72. PubMed ID: 21441550
    [Abstract] [Full Text] [Related]

  • 34. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.
    Braun J, Baraliakos X, Listing J, Sieper J.
    Arthritis Rheum; 2005 Aug 15; 52(8):2447-51. PubMed ID: 16052578
    [Abstract] [Full Text] [Related]

  • 35. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
    Charni N, Juillet F, Garnero P.
    Arthritis Rheum; 2005 Apr 15; 52(4):1081-90. PubMed ID: 15818703
    [Abstract] [Full Text] [Related]

  • 36. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept.
    Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J.
    J Rheumatol; 2004 Mar 15; 31(3):531-8. PubMed ID: 14994401
    [Abstract] [Full Text] [Related]

  • 37. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis.
    Choi ST, Kim JH, Kang EJ, Lee SW, Park MC, Park YB, Lee SK.
    Rheumatology (Oxford); 2008 Dec 15; 47(12):1775-9. PubMed ID: 18854347
    [Abstract] [Full Text] [Related]

  • 38. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety.
    Maksymowych WP, Jhangri GS, Lambert RG, Mallon C, Buenviaje H, Pedrycz E, Luongo R, Russell AS.
    J Rheumatol; 2002 May 15; 29(5):959-65. PubMed ID: 12022358
    [Abstract] [Full Text] [Related]

  • 39. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.
    de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, van Denderen JC, Dijkmans BA, Wolbink GJ.
    Ann Rheum Dis; 2009 Apr 15; 68(4):531-5. PubMed ID: 18375542
    [Abstract] [Full Text] [Related]

  • 40. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
    Buch MH, Seto Y, Bingham SJ, Bejarano V, Bryer D, White J, Emery P.
    Arthritis Rheum; 2005 Jan 15; 52(1):42-8. PubMed ID: 15641046
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.